Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Q3 Revenues Rise

NEW YORK, Oct. 29 (GenomeWeb News) - Harvard Bioscience, the parent company of Genomic Solutions, late yesterday reported increased revenues for the third quarter.

 

The company's revenues for the quarter came to $21.1 million, up from $12.8 million for the third quarter of 2002. Net income was $986,000, compared to an $82,000 loss for the same period last year.

 

"[I]t is primarily the impact of the new products we have added through the acquisitions of Genomic Solutions, BTX, GeneMachines and most recently, BioRobotics that were the major contributors to our success for the quarter," Harvard Bioscience CEO Chane Graziano said in a statement.

 

R&D expenses totaled $1.6 million, up from $1 million for the same period last year.

 

At the end of the quarter the company had $7.6 million in cash and cash equivalents, compared with $15.3 million as of December 31, 2002.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.